LG262: Translate Big Biomedical Data to Improve Human Health

Date: 
Friday, March 4, 2016 - 12:00
Speaker: 
Rong Xu, PhD
Abstract: 
Dr. Xu is an Assistant Professor in the Department of Epidemiology and Biostatistics in the School of Medicine, Case Western Reserve University. Dr. Xu has deep knowledge in both biomedical research and computer science. Dr. Xu earned her BS degree in Biology from Peking University and MS degree in Biology from Case Western Reserve University. Dr. Xu received her Ph.D. in Biomedical Informatics and M.S in Computer Science from Stanford University. Dr. Xu was selected as a Siebel Scholar in 2004 for her outstanding academic performance and leadership in computer science. Dr. Xu received the 2014 NIH Director's New Innovator Award that supports exceptionally creative new investigators who propose highly innovative projects that have the potential for unusually high impact. She received the 2015 Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research, which recognizes the outstanding achievement of a junior faculty for novel, high-risk, high-reward cancer prevention research.  Dr. Xu also received the American Medical Informatics Association (AMIA) New Investigator Award, which was established to recognize the outstanding achievement of a junior faculty in the field of medical informatics on the basis of scientific merit and research excellence.   Dr. Xu’s  research seeks both to reveal the mechanisms that underlie human diseases and discover new drug treatments to combat them. Dr. Xu develops natural language processing, machine learning, data mining, statistical learning, systems biology, and other advanced computational techniques that can create, integrate, and analyze large amounts of heterogeneous and complex biological and health data. Dr. Xu’s research interests in computer science include: natural language processing, systems biology, machine learning, data mining, ontology, knowledge representation and engineering, imaging retrieval. Her research interests in biomedical sciences include: drug discovery, disease gene discovery, human gut microbiome, drug toxicity prediction, pharmacogenetics and pharmacogenomics, and post-market drug safety surveillance. In this talk, Dr. Xu will briefly talk about: (1) Automatic extraction of disease phenotypic relationships from biomedical literature; (2) Post-marketing drug safety signal detection from the FDA Adverse Event Reporting (FAERS) system; (3) Disease image retrieval from the Web; (4) Phenome-wide systems approaches for disease gene prediction; (5) Combining novel computational drug repositioning approaches and biological validation for ovarian cancer drug discovery; and (6) Genome-wide systems approaches to understand how human gut microbiome contributes to colorectal cancer.